Background:Hematopoietic stem cell transplantation (HSCT) is a potentially curative procedure that is used in various hematological malignancies. However, among an increasing number of HSCT, the amount of cancer therapy-related cardiac dysfunction (CTRCD) is increasing as well. This study aimed to determine the prevalence of subclinical CTRCD in HSCT patients 12 months after HSCT and to assess the impact of clinical factors on the development of CTRCD.Material and Methods: We included 55 patients who underwent autologous or allogeneic HSCT. The patients were assessed using an echocardiography method before and 12 months after a HSCT procedure.Results:Our study revealed that during the 12-month follow-up period, asymptomatic CTRCD was observed in 15 patients (27.3%), 6 experienced moderate CTRCD, and 9 experienced mild CTRCD. Patients with previous use of anthracyclines tended to have CTRCD more often: nine patients (60%) in the CTRCD group and nine patients (22.5%) in non-CTRCD group. Patients who received the BEAM regimen for conditioning also experienced CTRCD more often: five patients (33.3%) in CTRCD group vs. two patients (5%) in the non-CTRCD group.Conclusions: Our study showed that asymptomatic CTRCD was found in 27.3% of the patients 12 months after HSCT. The BEAM chemotherapy conditioning protocol following prior anthracycline use were identified as factors contributing to the development of CTRCD.
背景：造血干细胞移植（HSCT）是一种具有潜在治愈效果的治疗方法，广泛应用于多种血液系统恶性肿瘤。然而，随着HSCT数量的增加，癌症治疗相关心功能障碍（CTRCD）的发生率也在上升。本研究旨在确定HSCT患者术后12个月亚临床CTRCD的患病率，并评估临床因素对CTRCD发生的影响。 材料与方法：本研究纳入了55例接受自体或异体HSCT的患者。通过超声心动图方法在HSCT术前及术后12个月对患者进行评估。 结果：研究发现，在12个月的随访期内，15例患者（27.3%）出现无症状CTRCD，其中6例为中度CTRCD，9例为轻度CTRCD。既往使用过蒽环类药物的患者更易发生CTRCD：CTRCD组中有9例（60%），而非CTRCD组中为9例（22.5%）。接受BEAM方案预处理的患者也更容易出现CTRCD：CTRCD组中有5例（33.3%），而非CTRCD组中仅有2例（5%）。 结论：本研究表明，HSCT术后12个月，27.3%的患者存在无症状CTRCD。既往蒽环类药物使用史及BEAM化疗预处理方案被确定为促进CTRCD发生的影响因素。
肿瘤(癌症)患者之家